Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001088875-25-000022
Filing Date
2025-02-12
Accepted
2025-02-12 10:25:35
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5634
  Complete submission text file 0001088875-25-000022.txt   7489
Mailing Address CALTON SQUARE 1 GREENSIDE ROW EDINBURGH X0 EH13AN
Business Address CALTON SQUARE 1 GREENSIDE ROW EDINBURGH X0 EH13AN 00441312752000
BAILLIE GIFFORD & CO (Filed by) CIK: 0001088875 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0
Type: SCHEDULE 13G/A

Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Subject) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88833 | Film No.: 25612876
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)